Meta-analysis:: proton pump inhibitors vs. H2-receptor antagonists -: their efficacy with antibiotics in Helicobacter pylori eradication

被引:45
作者
Gisbert, JP
Khorrami, S
Calvet, X
Gabriel, R
Carballo, F
Pajares, JM
机构
[1] Univ Hosp La Princesa, Dept Gastroenterol, Madrid, Spain
[2] Corp Parc Tauli, Med Serv, Barcelona, Spain
[3] Univ Hosp La Princesa, Dept Clin Epidemiol, Madrid, Spain
[4] Univ Hosp Guadalajara, Dept Gastroenterol, Guadalajara, Spain
关键词
D O I
10.1046/j.1365-2036.2003.01766.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: It is unknown whether proton pump inhibitors are superior to H-2-receptor antagonists in Helicobacter pylori eradication regimens. Aim: To perform a meta-analysis comparing the efficacy of both antisecretors when co-prescribed with antibiotics. Methods: Randomized clinical trials comparing proton pump inhibitors vs. H-2-receptor antagonists with the same antibiotics were selected. Data sources included PubMed, the Cochrane Controlled Trials Register and abstracts from congresses up to January 2002. A meta-analysis was performed by combining the odds ratios. Results: Twenty studies fulfilled the inclusion criteria. In the intention-to-treat analysis, the mean eradication rates with proton pump inhibitors and H-2-receptor antagonists plus antibiotics were 74% [95% confidence interval (CI), 71-76%] and 69% (95% CI, 66-71%), respectively. The odds ratio for this comparison was 1.31 (95% CI, 1.09-1.58). The number needed to treat with proton pump inhibitors to achieve eradication success, compared with H-2-receptor antagonists, was 25. When studies prescribing very high doses of H-2-receptor antagonists (two of the outliers) were excluded, the odds ratio (for proton pump inhibitors vs. H-2-receptor antagonists) increased to 1.37, the number needed to treat decreased to 20 and the heterogeneity between the studies decreased. Conclusions: Overall, proton pump inhibitors are more effective than H-2-receptor antagonists when prescribed at usual doses with antibiotics to eradicate H. pylori infection.
引用
收藏
页码:757 / 766
页数:10
相关论文
共 75 条
[1]  
ADAMEK RJ, 1995, GASTROENTEROLOGY, V108, pA44
[2]   In vitro activity of ebrotidine, ranitidine, omeprazole, lansoprazole, and bismuth citrate against clinical isolates of Helicobacter pylori [J].
Alarcón, T ;
Domingo, D ;
Sánchez, I ;
Sanz, JC ;
Martínez, MJ ;
López-Brea, M .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1998, 17 (04) :275-277
[3]   In vitro activity of omeprazole in combination with several antimicrobial agents against clinical isolates of Helicobacter pylori [J].
Alarcon, T ;
Domingo, D ;
Sanchez, I ;
deRojas, FD ;
LopezBrea, M .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1996, 15 (12) :937-940
[4]  
ALASSI MT, 1995, AM J GASTROENTEROL, V90, P1411
[5]  
Bardhan KD, 2000, ALIMENT PHARM THERAP, V14, P59
[6]   DOUBLE-BLIND TRIAL OF OMEPRAZOLE AND AMOXICILLIN TO CURE HELICOBACTER-PYLORI INFECTION IN PATIENTS WITH DUODENAL-ULCERS [J].
BAYERDORFFER, E ;
MIEHLKE, S ;
MANNES, GA ;
SOMMER, A ;
HOCHTER, W ;
WEINGART, J ;
HELDWEIN, W ;
KLANN, H ;
SIMON, T ;
SCHMITT, W ;
BASTLEIN, E ;
EIMILLER, A ;
HATZ, R ;
LEHN, N ;
DIRSCHEDL, P ;
STOLTE, M .
GASTROENTEROLOGY, 1995, 108 (05) :1412-1417
[7]   OMEPRAZOLE ENHANCES EFFICACY OF TRIPLE THERAPY IN ERADICATING HELICOBACTER-PYLORI [J].
BORODY, TJ ;
ANDREWS, P ;
FRACCHIA, G ;
BRANDL, S ;
SHORTIS, NP ;
BAE, H .
GUT, 1995, 37 (04) :477-481
[8]  
Breuer T, 1999, ALIMENT PHARM THERAP, V13, P567
[9]   Clarithromycin, amoxycillin and H-2-receptor antagonist therapy for Helicobacter pylori peptic ulcer disease in Korea [J].
Breuer, T ;
Kim, JG ;
ElZimaity, HMT ;
Nikajima, S ;
Ota, H ;
Osato, M ;
Graham, DY .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1997, 11 (05) :939-942
[10]  
Carvalho AST, 1998, GUT, V43, pA74